跳至主要内容
临床试验/JPRN-UMIN000010138
JPRN-UMIN000010138已完成未知

Prognostic evaluation for renal anemia patients on hemodialysis based upon hemoglobin levels during treatment with Epoetin Beta Pegol: multicenter prospective study - PARAMOUNT-HD Study

EP CRSU Co., Ltd.0 个研究点目标入组 530 人开始时间: 2013年3月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
530

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (randomized study part) (1) Anemia for other reasons than the renal anemia:Complication of apparent hemorrhagic lesion, hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia), or apparent chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease) (2) Hypersensitivity to epoetin beta pegol, erythropoietin, or darbepoetin alfa (3) Complication of malignant tumor (4) Pregnancy, nursing or planning to become pregnant during the study (women only) (5) Judged as ineligible to the randomized study in the opinion of the investigator (observational study part) 1.Hypersensitivity to epoetin beta pegol, erythropoietin, or darbepoetin alfa 2.Pregnancy, nursing or planning to become pregnant during the study (women only) 3.Judged as ineligible to the randomized study in the opinion of the investigator

研究者

发起方
EP CRSU Co., Ltd.

相似试验